|
注册号: Registration number: |
ChiCTR2500098572 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-11 09:16:42 |
|
注册时间: Date of Registration: |
2025-03-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
α-亚麻酸对认知功能和肠道菌群的作用 |
|
Public title: |
Role of alpha-linolenic acid on cognitive function and gut flora |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
α-亚麻酸对轻度认知功能障碍人群的干预研究 |
|
Scientific title: |
An intervention study of alpha-linolenic acid in a population with mild cognitive impairment |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
殷佳伟 |
研究负责人: |
殷佳伟 |
|
Applicant: |
Jiawei Yin |
Study leader: |
Jiawei Yin |
|
申请注册联系人电话: Applicant telephone: |
+86 132 3713 3707 |
研究负责人电话:
Study leader's |
+86 132 3713 3707 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yinjiawei@cqmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
yinjiawei@cqmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市沙坪坝区虎溪街道大学城中路61号 |
研究负责人通讯地址: |
重庆市沙坪坝区虎溪街道大学城中路61号 |
|
Applicant address: |
No. 61, Middle Road, University Town, Huxi Street, Shapingba District, Chongqing, China |
Study leader's address: |
No. 61, Middle Road, University Town, Huxi Street, Shapingba District, Chongqing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学公共卫生学院营养与食品卫生学教研室 |
||
|
Applicant's institution: |
Department of Nutrition and Food Hygiene, School of Public Health, Chongqing Medical University, China |
||
|
研究负责人所在单位: |
重庆医科大学公共卫生学院营养与食品卫生学教研室 |
||
|
Affiliation of the Leader: |
Department of Nutrition and Food Hygiene, School of Public Health, Chongqing Medical University, China |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024135 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学医学研究伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Research Ethics Committee of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-10 00:00:00 | ||
|
伦理委员会联系人: |
洪玥铃 |
||
|
Contact Name of the ethic committee: |
Hong Yueling |
||
|
伦理委员会联系地址: |
重庆市渝中区医学院路1号 |
||
|
Contact Address of the ethic committee: |
No. 1, Medical College Road, Yuzhong District, Chongqing City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6848 6646 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆医科大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区虎溪街道大学城中路61号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 61, Middle Road, University Town, Huxi Street, Shapingba District, Chongqing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chongqing Natural Science Foundation |
||||||||||||||||||||||
|
研究疾病: |
轻度认知障碍 |
||||||||||||||||||||||
|
Target disease: |
mild cognitive impairment |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)探索ALA 与 MCI 患病风险及发病风险的量效关系。 (2)探索ALA 干预对 MCI 人群认知功能的影响。 (3)探索ALA 能否通过调节肠道菌群及其代谢产物进而发挥改善认知功能的作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To explore the quantitative and qualitative relationship between ALA and the risk of MCI and the risk of morbidity. (2) To explore the effect of ALA intervention on cognitive function in MCI population. (3) To explore whether ALA can improve cognitive function by regulating intestinal flora and its metabolites. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.可能引起认知功能障碍的神经系统疾病患者; 2.抑郁、狂躁、焦虑等精神疾病史者; 3.严重肝、肾功能障碍者; 4.头部严重创伤史以及特殊药物服用史者; 5.严重感知觉障碍,不能完成认知功能测定者。 6.近一个月服用维生素补充剂,鱼油胶囊、紫苏籽油、亚麻籽油胶囊等补充剂,且拒绝在干预期间停止服用除干预物以外的其他营养补充剂; 7.近一个月每天核桃摄入量超过 20g 或每周多脂鱼类摄入超100g; 8.烹调用油为亚麻籽油等富含 ALA 的植物油; 9.近一个月内连续服用抗生素超过三天; 10.未按规定食用受试样品,或资料不全,影响到功效或安全性判断者;受试期间不配合项目安排者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with neurological disorders that may cause cognitive dysfunction; 2. People with a history of depression, mania, anxiety, and other psychiatric disorders; 3. Patients with severe hepatic and renal dysfunction; 4. Those with a history of severe head trauma and a history of special medications; 5. Severe perceptual impairment and inability to complete cognitive function measurements. 6. Taking vitamin supplements, fish oil capsules, perilla seed oil, flaxseed oil capsules and other supplements in the last month, and refusing to stop taking nutritional supplements other than the intervention during the intervention period; 7. Consumption of walnuts exceeds 20g per day or 100g per week of fatty fish in the last month; 8. Cooking oil used is ALA-rich vegetable oil (e.g., flaxseed oil); 9. Continuous antibiotic use for more than three days within the past month; 10. Failure to consume the test samples as required, incomplete documentation affecting efficacy or safety evaluation, or non-compliance with project arrangements during the trial period. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-01 00:00:00 至 To 2025-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究负责人采用分层随机化的方法产生 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generated by the study leader using stratified randomisation. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
研究人员及受试者对自己所在组别及所受干预均不知情。 |
|
Blinding: |
The researchers and the subjects were unaware of their own groups and the interventions they were subjected to. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
可通过邮件联系项目负责人,由项目负责人确认后可获得数据集 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The dataset can be obtained by contacting the project leader by email, who will confirm the availability of the dataset. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:问卷和量表,数据管理:SAS,数据有课题组保存。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: questionnaires and scales, data management: SAS, data are kept by the subject group |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |